Ong YT, Andrade J, Armbruster M, Shi C, Castro M, Costa ASH, Sugino T, Eelen G, Zimmermann B, Wilhelm K, Lim J, Watanabe S, Guenther S, Schneider A, Zanconato F, Kaulich M, Pan D, Braun T, Gerhardt H, Efeyan A, Carmeliet P, Piccolo S, Grosso AR, Potente M

A YAP/TAZ-TEAD signalling module links endothelial nutrient acquisition to angiogenic growth.

Nat Metab 2022; 672-682. doi: 10.1038/s42255-022-00584-y

Zribi S, Giannitelli GJ, Bernardini L, Censi F, Camerini S, Bertuccini L, Iosi F, Giannella E, Sanchez M, Consoli E, Casagrande A, Cenci A, Floridia G, Novelli A, Giuliani A, Costanzo V, Crescenzi M, Pajalunga D

Structural obstruction to full DNA replication in terminally differentiated skeletal muscle cells.

EMBO Rep 2025; 4633-4655. doi: 10.1038/s44319-025-00554-x

Peña-Gómez MJ, Rodríguez-Martín Y, Del Rio Oliva M, Wijesekara Hanthi Y, Berrada S, Freire R, Masson JY, Reyes JC, Costanzo V, Rosado IV

HMCES corrupts replication fork stability during base excision repair in homologous recombination-deficient cells.

Sci Adv 2025; eads3227. doi: 10.1126/sciadv.ads3227

Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

Ann Oncol 2015; 2079-84. doi: 10.1093/annonc/mdv318

Moore CE, Yalcindag SE, Czeladko H, Ravindranathan R, Wijesekara Hanthi Y, Levy JC, Sannino V, Schindler D, Ciccia A, Costanzo V, Elia AEH

RFWD3 promotes ZRANB3 recruitment to regulate the remodeling of stalled replication forks.

J Cell Biol 2023; . doi: 10.1083/jcb.202106022

Hanthi YW, Ramirez-Otero MA, Appleby R, De Antoni A, Joudeh L, Sannino V, Waked S, Ardizzoia A, Barra V, Fachinetti D, Pellegrini L, Costanzo V

RAD51 protects abasic sites to prevent replication fork breakage.

Mol Cell 2024; 3026-3043.e11. doi: 10.1016/j.molcel.2024.07.004

Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Lancet Oncol 2013; 981-8. doi: 10.1016/S1470-2045(13)70310-3

Lewis M, Terré B, Knobel PA, Cheng T, Lu H, Attolini CS, Smak J, Coyaud E, Garcia-Cao I, Sharma S, Vineethakumari C, Querol J, Gil-Gómez G, Piergiovanni G, Costanzo V, Peiró S, Raught B, Zhao H, Salvatella X, Roy S, Mahjoub MR, Stracker TH

GEMC1 and MCIDAS interactions with SWI/SNF complexes regulate the multiciliated cell-specific transcriptional program.

Cell Death Dis 2023; 201. doi: 10.1038/s41419-023-05720-4

Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB

Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.

Clin Cancer Res 2014; 5663-71. doi: 10.1158/1078-0432.CCR-14-0719

Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schöffski P, Voest EE, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

Ann Oncol 2014; 1222-8. doi: 10.1093/annonc/mdu108

Mann A, Ramirez-Otero MA, De Antoni A, Hanthi YW, Sannino V, Baldi G, Falbo L, Schrempf A, Bernardo S, Loizou J, Costanzo V

POLθ prevents MRE11-NBS1-CtIP-dependent fork breakage in the absence of BRCA2/RAD51 by filling lagging-strand gaps.

Mol Cell 2022; 4218-4231.e8. doi: 10.1016/j.molcel.2022.09.013

Schrempf A, Bernardo S, Arasa Verge EA, Ramirez Otero MA, Wilson J, Kirchhofer D, Timelthaler G, Ambros AM, Kaya A, Wieder M, Ecker GF, Winter GE, Costanzo V, Loizou JI

POLθ processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells.

Cell Rep 2022; 111716. doi: 10.1016/j.celrep.2022.111716

Donzelli S, Cioce M, Sacconi A, Zanconato F, Daralioti T, Goeman F, Orlandi G, Di Martino S, Fazio VM, Alessandrini G, Telera S, Carosi M, Ciliberto G, Botti C, Strano S, Piccolo S, Blandino G

A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions.

Mol Cancer 2022; 152. doi: 10.1186/s12943-022-01617-6

de Marinis F, Atmaca A, Tiseo M, Giuffreda L, Rossi A, Gebbia V, D'Antonio C, Dal Zotto L, Al-Batran SE, Marsoni S, Wolf M

A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.

J Thorac Oncol 2013; 1091-4. doi: 10.1097/JTO.0b013e318293d88c

Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.

Eur J Cancer 2013; 290-6. doi: 10.1016/j.ejca.2012.09.009

%PLACEHOLDER%